frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 21 November 2025
DOI 10.3389/fimmu.2025.1734343

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Chandra Mohan
cmohan@central.uh.edu
Richard C. Willson
willson@uh.edu

†These authors share senior authorship

RECEIVED 28 October 2025
ACCEPTED 30 October 2025
PUBLISHED 21 November 2025

CITATION
Lei R, Vu B, Kourentzi K, Soomro S, Danthanarayana AN, Brgoch J, Nadimpalli S, Petri M, Mohan C and Willson RC (2025) Correction: A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. *Front. Immunol.* 16:1734343. doi: 10.3389/fimmu.2025.1734343

Correction: A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM

Rongwei Lei[1], Binh Vu[2], Katerina Kourentzi[2], Sanam Soomro[1], Adheesha N. Danthanarayana[3], Jakoah Brgoch[3], Suma Nadimpalli[1], Michelle Petri[4], Chandra Mohan[1*†] and Richard C. Willson[2,5,6*†]

[1]Department of Biomedical Engineering, University of Houston, Houston, TX, United States, [2]William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, United States, [3]Department of Chemistry, University of Houston, Houston, TX, United States, [4]Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, [5]Department of Biology and Biochemistry, University of Houston, Houston, TX, United States, [6]Escuela de Medicina y Ciencias de Salud, Tecnológico de Monterrey, Monterrey, NL, Mexico

KEYWORDS

lupus nephritis, nanophosphors, lateral flow assay, biomarker, diagnostic

A Correction on

A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM

By Lei R, Vu B, Kourentzi K, Soomro S, Danthanarayana AN, Brgoch J, Nadimpalli S, Petri M, Mohan C and Willson RC (2022) *Front. Immunol.* 13:1044743. doi: 10.3389/fimmu.2022.1044743

The **Conflict of interest** statement was erroneously given as: "RW is a named inventor on IP covering the use of nanophosphors in lateral flow assays, and may receive income from its commercialization by Clip Health, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest".

The correct **Conflict of interest** statement is "RW is a named inventor on IP covering the use of nanophosphors in lateral flow assays, and may receive income from its commercialization by Clip Health, Inc. Authors RW, KK and BV acknowledge their financial interest in Glow Nanotech which at the time was developing a different LFA technology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest".

The original version of this article has been updated.

Publisher's note